Metropolitan Life Insurance Co. NY increased its holdings in Collegium Pharmaceutical Inc (NASDAQ:COLL) by 412.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,124 shares of the specialty pharmaceutical company’s stock after buying an additional 8,954 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Collegium Pharmaceutical were worth $191,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Meeder Asset Management Inc. boosted its position in shares of Collegium Pharmaceutical by 644.8% in the 4th quarter. Meeder Asset Management Inc. now owns 3,672 shares of the specialty pharmaceutical company’s stock worth $62,000 after buying an additional 3,179 shares in the last quarter. Oregon Public Employees Retirement Fund purchased a new stake in shares of Collegium Pharmaceutical in the 4th quarter worth about $103,000. State Board of Administration of Florida Retirement System boosted its position in shares of Collegium Pharmaceutical by 4.8% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 14,359 shares of the specialty pharmaceutical company’s stock worth $247,000 after buying an additional 655 shares in the last quarter. Jefferies Group LLC purchased a new stake in shares of Collegium Pharmaceutical in the 3rd quarter worth about $271,000. Finally, Man Group plc purchased a new stake in shares of Collegium Pharmaceutical in the 3rd quarter worth about $287,000.
In other news, Director Michael Thomas Heffernan sold 25,000 shares of the company’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $17.17, for a total transaction of $429,250.00. Following the completion of the transaction, the director now owns 227,362 shares of the company’s stock, valued at approximately $3,903,805.54. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 8.08% of the company’s stock.
Shares of COLL stock opened at $14.66 on Tuesday. Collegium Pharmaceutical Inc has a twelve month low of $13.10 and a twelve month high of $28.91. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.21 and a current ratio of 1.26.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, February 27th. The specialty pharmaceutical company reported $0.27 earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.65. Collegium Pharmaceutical had a negative net margin of 13.95% and a negative return on equity of 41.12%. The firm had revenue of $73.40 million during the quarter, compared to the consensus estimate of $72.71 million. During the same quarter in the previous year, the company posted ($0.54) EPS. The firm’s revenue for the quarter was up 579.6% on a year-over-year basis. On average, equities research analysts predict that Collegium Pharmaceutical Inc will post -0.25 EPS for the current fiscal year.
Several equities research analysts recently commented on the stock. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research report on Monday. Cantor Fitzgerald set a $35.00 target price on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Friday. Janney Montgomery Scott assumed coverage on shares of Collegium Pharmaceutical in a research note on Friday. They issued a “buy” rating and a $29.00 target price for the company. ValuEngine raised shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Wednesday, April 3rd. Finally, BidaskClub downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, March 26th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $28.67.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Zolmax and is the sole property of of Zolmax. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://zolmax.com/investing/metropolitan-life-insurance-co-ny-acquires-8954-shares-of-collegium-pharmaceutical-inc-coll/3038655.html.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Featured Article: Why Net Income is Important to Investors
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.